<!doctype html><html lang="zh-hans"><head><meta charset="utf-8"><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"><title>我们应该如何追求人类的长寿呢？</title><link rel="stylesheet" href="https://stackpath.bootstrapcdn.com/bootstrap/4.3.1/css/bootstrap.min.css" integrity="sha384-ggOyR0iXCbMQv3Xipma34MD+dH/1fQ784/j6cY/iJTQUOhcWr7x9JvoRxT2MZw1T" crossorigin="anonymous"><link rel="stylesheet" href="/img/css.css?random="><link data-rh="true" rel="icon" href="/img/favicon.ico"/><script>var _hmt = _hmt || [];(function() {var hm = document.createElement("script");hm.src = "https://hm.baidu.com/hm.js?03c1a0f31299b4a2fbb83c34d6beaac9";var s = document.getElementsByTagName("script")[0]; s.parentNode.insertBefore(hm, s);})();</script><script data-ad-client="ca-pub-6067137220025946" async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script><script type="text/javascript" src="https://platform-api.sharethis.com/js/sharethis.js#property=5effb96910009800120b8d4d&product=inline-share-buttons" async="async"></script></head><body><div id="my_header"><div class="container"><nav class="navbar navbar-expand-lg"><a class="navbar-brand" href="/"><img alt="diglog" src="/img/logo.v1.gif" class="rounded-sm"></a><button class="navbar-toggler" type="button" data-toggle="collapse" data-target="#navbarNavAltMarkup" aria-controls="navbarNavAltMarkup" aria-expanded="false" aria-label="Toggle navigation"><span class="navbar-toggler-icon"></span></button><div class="collapse navbar-collapse" id="navbarNavAltMarkup"><div class="navbar-nav"></div></div></nav></div></div><div class="container"><div id="my_content"><h1 class="page_narrow">我们应该如何追求人类的长寿呢？</h1><div class="row"><div class="col-lg-12 col-12"><div class="my_story_list_item shadow p-3 mb-5 bg-white rounded"><div class="story_page_pub_time page_narrow">2020-10-27 10:25:17</div><div class="page_narrow text-break page_content"><p>Unlike human beings, the debate over the question “should people live forever, if they want?” never seems to die.</p><p>与人类不同的是，关于“如果人们想要长生不老，应该长生不老吗？”这个问题的争论。似乎永远不会死。</p><p> This is surprising given that the answer is obviously “yes.”In fact the arguments for “no” are so unimpressive I’m relegating them to an  Appendix.</p><p>这是令人惊讶的，因为答案显然是“是的”。事实上，“不”的论点是如此平淡无奇，我将它们归类到附录中。</p><p> But what if you, like me, are curious about the inevitable next question:  “should I work on human longevity, and if so, how?&#34;  1</p><p>但是，如果你和我一样，对不可避免的下一个问题感到好奇：“我应该研究人类的长寿吗？如果应该，如何研究？”</p><p> This is ultimately a personal question, and what follows won’t answer it for you (or for me, frankly).But answering it also requires understanding a shedload of strategic and economic considerations.I couldn’t find a comprehensive guide to them, so here’s a start at one.</p><p>这归根结底是个个人问题，下面的问题不能回答你(或者坦率地说，对我来说)。但回答这个问题也需要了解大量的战略和经济考虑。我找不到一个全面的指南，所以这里就从一个开始。</p><p>     “We now have the understanding of biology to work on therapies that directly address the root causes of aging.”</p><p>“我们现在对生物学有了理解，可以致力于直接解决衰老根源的疗法。”</p><p> Is this true? And if so what’s the best way to go about it? There are (at least) three big considerations.</p><p>这是真的吗？如果是这样的话，最好的办法是什么呢？(至少)有三大考虑因素。</p><p>   Here’s a summary of what experts think causes aging in mammals and how they figured them out.</p><p>以下是专家们认为是什么导致哺乳动物衰老，以及他们是如何解决这些问题的。</p><p> Free radical theory of aging proposed in 1956. Strong evidence in 1990s that DNA damage leads to aging. Still not confirmed that DNA repair leads to longevity.</p><p>1956年提出的衰老自由基理论。20世纪90年代的有力证据表明，DNA损伤会导致衰老。DNA修复是否能延长寿命仍未得到证实。</p><p>  Stem cells discovered 1963. Causal connection between stem cell exhaustion and aging first demonstrated in 2012.</p><p>干细胞在1963年被发现。干细胞耗竭和衰老之间的因果关系在2012年首次得到证实。</p><p>  Replicative senescence described by Hayflick in 1965. Oncogene-induced senescence described starting in 1980s. Stress-induced senescence described starting in 1990s. Tumor suppressor loss-induced senescence described starting in 2000s. Strong evidence of therapeutic potential in 2011.</p><p>海弗里克在1965年描述了复制性衰老。癌基因诱导的衰老描述始于20世纪80年代。据描述，压力诱导的衰老始于20世纪90年代。肿瘤抑制因子缺失诱导衰老的描述始于21世纪头10年。2011年具有治疗潜力的有力证据。</p><p>  Mitochondrial free radical theory proposed in 1972, now much less clear that it&#39;s correct. Non-ROS damage hypothesis made in 2005, evidence still accumulating.</p><p>线粒体自由基理论于1972年提出，现在还不太清楚它是否正确。2005年提出的非活性氧损伤假说，证据仍在不断积累。</p><p>    Discovery of telomere structure and speculation about connections to replicative senescence in 1980s. Telomere loss hypothesis for aging proposed in 1991. Experimental evidence confirming connection in 1998.</p><p>20世纪80年代端粒结构的发现和与复制衰老关系的推测。1991年提出的衰老端粒丢失假说。1998年的实验证据证实了两者之间的联系。</p><p>  Evidence starting to accumulate by 1983. Demonstration of causal role of chaperone system in mice in 2008. Demonstration of causal role for autophagy in mice in 2013.</p><p>到1983年，证据开始积累起来。2008年小鼠伴侣系统因果作用的演示。2013年小鼠自噬因果作用的演示。</p><p>      Heterochromatin loss model of aging proposed in 1997. Evidence accumulates for chromatin structure disruption at all levels in 2010s.</p><p>1997年提出的异染色质老化损失模型。在2010年代，所有水平的染色质结构破坏的证据越来越多。</p><p>  Nintil’s  Longevity FAQ is a great starting point to understand the biology behind most of these proposed causes if you’re unfamiliar.</p><p>如果你不熟悉，NINTIL的长寿常见问题解答是一个很好的起点，可以帮助你理解这些提出的大多数原因背后的生物学原理。</p><p> Let’s first admit that it’s dubious to break down aging into discrete causes like in the table above. Here’s a diagram giving a much more detailed view of our current understanding of aging-related processes.Based that diagram (seriously, click the link, it’s worth it), understanding the causality of aging may be less about discovering new causes and more about disentangling what we already semi-understand, if  that’s even possible.</p><p>让我们首先承认，像上表那样将衰老分解成不连续的原因是值得怀疑的。这张图更详细地展示了我们目前对衰老相关过程的理解。根据这张图(说真的，点击链接，这是值得的)，理解衰老的因果关系可能不是发现新的原因，而是更多地解开我们已经半了解的东西，如果这是可能的话。</p><p> Nevertheless, from the outside view the above table doesn’t really suggest that we’ve finished discovering fundamental causes of aging.The pattern — if small-N history can have patterns — seems to be that every decade a couple biological processes are associated with aging and then 1+ decades later, if ever, a causal connection is established.The table only includes causes of aging that have made their way into big general reviews, so we wouldn’t expect to, and don’t, see any with initial discovery dates past 2000.Biological processes whose heydays came after 2000 that might someday make it into this table include  microbiome changes and  RNAi dysregulation.</p><p>然而，从外部来看，上面的表格并不能真正表明我们已经发现了衰老的根本原因。模式-如果小N历史可以有模式的话-似乎是每十年就有几个生物过程与衰老有关，然后如果有的话，十多年后，因果关系就会建立起来。表格只包括已经进入大型综合评论的衰老原因，所以我们不会期望也不会看到任何最初发现日期超过2000年的生物过程，这些过程可能有一天会进入这个表格，包括微生物群变化和RNAi失调。</p><p> From the inside view you might contradict this by accounting for increasing  investment into aging research.If investment has increased but the rate of discoveries hasn’t changed, that might mean we’re nearly done discovering things.In the same spirit you could contrast the improvement in biotech tools to the seemingly-constant rate of discoveries.</p><p>从内部来看，你可能会用增加对老龄化研究的投资来解释这一点。如果投资增加了，但发现的速度没有改变，那可能意味着我们几乎完成了发现。本着同样的精神，你可以将生物技术工具的改进与看似恒定的发现速度进行对比。</p><p> Still, while we clearly know more about aging than we ever have, I’m hesitant to believe any claims of causal understanding.</p><p>不过，尽管我们对衰老的了解显然比以往任何时候都多，但我还是不敢相信任何因果理解的说法。</p><p>  The  standard playbook for making a new therapeutic (the catch-all name for a drug or medical treatment) is called a  target-based approach, and goes like this:</p><p>制造一种新疗法(一种药物或医疗的统称)的标准策略被称为基于目标的方法，如下所示：</p><p> Identify a specific biological process that’s causing the disease you want to treat (e.g. plaque buildup, the expression of a single gene, a protein key to a virus’s function)</p><p>确定导致您想要治疗的疾病的特定生物过程(例如，斑块堆积、单个基因的表达、病毒功能的关键蛋白质)。</p><p> Find a way to interfere with it (e.g. a synthetic molecule, an engineered antibody, a surgical intervention)  in vitro or in an animal model</p><p>找到一种在体外或动物模型中干扰它的方法(例如，合成分子、工程抗体、外科干预)。</p><p>  Target-based approaches work best when we have a good handle on the cause, or small number of causes, of a disease.Bacterial infections and  single-gene disorders are good examples.But as discussed above aging seems to be massively multi-causal, not to mention that we probably haven’t found all the granular causes.</p><p>当我们很好地处理一种疾病的原因或少数原因时，基于目标的方法效果最好。细菌感染和单基因疾病就是很好的例子。但正如上面讨论的那样，衰老似乎是多种原因造成的，更不用说我们可能还没有发现所有的颗粒性原因。</p><p>  Set up an experiment where you can cheaply try a gajillion treatments and find one that affects the phenotype you care about (e.g. the phenotype of not being dead)</p><p>建立一个实验，你可以廉价地尝试无数的治疗方法，并找到一种影响你所关心的表型(例如，活着的表型)的疗法。</p><p> In reality all therapeutic development takes place on a spectrum between target-based and phenotypic.Some understanding of causality is necessary for restricting the space of treatments screened in phenotypic approaches.And many causes of phenotypes are discovered via screening approaches.But therapeutic development today generally  leans toward target-based.</p><p>事实上，所有的治疗发展都是在靶向和表型之间进行的，对因果关系的理解是限制表型筛选的治疗空间的必要条件，许多表型的原因都是通过筛查的方法发现的，但今天的治疗发展普遍倾向于靶向。</p><p> This is despite the fact that more first-in-class small molecule drugs are  developed with phenotypic approaches.And despite the fact that many effective longevity therapies (in mice) had no mechanistic hypothesis when they were discovered, including parabiosis (and potentially  neutral blood exchange), which we still don’t understand, and caloric restriction.</p><p>尽管事实上更多一流的小分子药物是用表型方法开发的，而且尽管许多有效的长寿疗法(在老鼠身上)在被发现时没有机械性假设，包括我们仍然不了解的异生(和潜在的中性血液交换)，以及热量限制。</p><p> Phenotypic approaches also seem better suited to finding effective combinations of therapies, for the inelegant reason that biological systems are so interconnected that to find an effective combination therapy we’ll just have to try a lot of combinations.This is important for longevity, since it’s not clear how much partial credit we get for solving any single cause of aging.It may be that each one cured buys us more lifespan and eventually we reach  longevity escape velocity.But since dying only requires one cause of death, we may need therapies that simultaneously address all or most causes of aging — even ones we don’t know of yet — before seeing benefits.The idea that phenotypic approaches might be better for targeting multi-causal biological phenomena like aging is  not new.Companies working on them (not specifically on longevity) include  Recursion,  Janssen, and  Insitro.</p><p>表型方法似乎也更适合于寻找有效的治疗组合，因为生物系统是如此相互关联，以至于要找到有效的组合疗法，我们只需要尝试很多组合。这对长寿很重要，因为还不清楚我们解决了任何单一的衰老原因得到了多少部分信任。可能每个治愈的方法都能为我们赢得更多的寿命，最终我们会达到长寿的逃逸速度。但既然死亡只需要一个死因，在看到益处之前，我们可能需要同时解决所有或大多数导致衰老的原因的疗法-即使是我们还不知道的原因。表型方法可能更适合于针对衰老等多原因生物现象的想法并不新鲜。致力于研究这些现象的公司(不是专门研究长寿的)包括Recursion，Janssen和Insitro。</p><p> Phenotypic screening has plenty of challenges, of course.One is the gajillion factor: you need a way to try lots of different treatments, and the space of possible treatments is astronomical.Another is that you can’t do a phenotypic screen without a phenotype, and waiting for animals to die is pretty inefficient.Developing measurable phenotypes for aging, like  epigenetic clocks, is critical to enable better phenotypic screens. Gordian,  Nemalife,  Magnitude,  InVivo,  Vium, and  Spring are among the companies working on these problems.</p><p>当然，表型筛选有很多挑战。一个是巨大的因素：你需要尝试许多不同的治疗方法，而可能的治疗空间是天文数字。另一个是，没有表型你就不能进行表型筛选，等待动物死亡是相当低效的。开发可测量的衰老表型，比如表观遗传时钟，对于实现更好的表型筛选至关重要。Gordian、Nemalife、Magitment、InVivo、Vium和Spring都在致力于解决这些问题的公司之列。</p><p>  It seems inarguable that humans can live forever in the limit of arbitrarily fancy technology, though  some disagree.  2But whether death is conquerable not just eventually, but  with near-term tools and understanding, is not clear.To paraphrase  Lincoln: we don’t know whether we’ve sharpened the biotechnological axe enough to cut down the death tree.</p><p>人类可以在任意幻想的技术的限制下永生，这似乎是毋庸置疑的，尽管有些人不同意这一点。但死亡是否不仅最终可以战胜，而且是否可以用短期的工具和理解来征服，还不清楚。套用林肯的话说：我们不知道我们是否已经磨得足够锋利，可以砍下死亡之树。</p><p> This is a key question for longevity strategy.The more confident we are that existing therapeutic technologies can make a dent in aging, the more we should invest in using them.The less confident we are, the more we need to make new tools.</p><p>这是长寿战略的一个关键问题。我们越有信心现有的治疗技术可以延缓衰老，我们就越应该投资于使用它们。我们越不自信，我们就越需要制造新的工具。</p><p> One relevant datapoint is what modalities (a.k.a. types of therapeutics) are being used by companies currently working on longevity. As far as we know, it’s about 51% small molecule drugs, 16% biologics, 18% cell therapies, and 15% gene therapies.This skews more toward non-small-molecule therapeutics than the  industry average, which is what we might expect given that most of the causes of aging in the table above don’t have obvious targets for small molecule inhibition.It’s also a marginal indication that new tools are needed, since non-small-molecule therapeutics are newer and less straightforward to develop than small-molecule drugs (as if those were straightforward to develop in the first place).</p><p>一个相关的数据点是什么模态(也称为。目前致力于长寿的公司正在使用)。据我们所知，大约51%的小分子药物，16%的生物制剂，18%的细胞疗法和15%的基因疗法。这比行业平均水平更倾向于非小分子疗法，这是我们可以预期的，因为上面表格中的大多数导致衰老的原因没有明显的小分子抑制作用。这也是一个边缘迹象，表明需要新的工具，因为非小分子疗法比小分子药物更新，开发起来也不那么直接(就像那些从一开始就直接开发一样)。</p><p> Another datapoint is what we’ve managed to accomplish so far in mice.Here’s a table mostly derived from a table of  Laura Deming’s showing the greatest median lifespan increase that’s been achieved in mice by different therapeutic modalities.</p><p>另一个数据点是我们到目前为止在小鼠身上所取得的成就。这是一个表格，主要来源于劳拉·戴明的表格，显示了通过不同的治疗方法在小鼠身上实现的最大的中位寿命延长。</p><p>   Note that median lifespan is not maximum lifespan, and lifespan often increased for only one sex of mouse.</p><p>请注意，中位寿命并不是最长寿命，而且通常只有一种性别的老鼠的寿命会增加。</p><p> The top two modalities in mice, spontaneous mutation and GGT, can’t be used (legally) in humans.And I’d argue diet is off the table for practical reasons; we’re talking extreme diets.The remaining modalities are used in some form in humans.I left surgeries off the table since it’s too broad a category, but the ones relevant to humans give &lt;= 10% median lifespan increase.Also note that just because a lab chose to treat a mouse with one modality doesn’t mean another modality can’t accomplish the same effect.Developing small molecule drugs to target proteins encoded by genes discovered by GGT in mice is standard practice.</p><p>老鼠身上最大的两种方式，自发突变和GGT，不能(合法地)用于人类。我认为出于实际原因，饮食不在考虑之列；我们谈论的是极端饮食。其余的方式在人类身上以某种形式使用。我没有讨论手术，因为它是一个太宽泛的类别，但与人类相关的给出了&lt；还要注意的是，仅仅因为实验室选择用一种方式治疗老鼠，并不意味着另一种方式就不能达到同样的效果。开发小分子药物来靶向由GGT在小鼠身上发现的基因编码的蛋白质是标准做法。</p><p> You can read this table as showing that human-amenable modalities are less potent than they could be, or you can read it as a selection effect of what academics find easiest to do in the lab.The former is a big claim, and I’d need more evidence to believe it.The latter isn’t news to anyone.Synthesizing candidate drug molecules is  slow.Producing immunotherapeutics is  slow and  hard.Gene therapy has a  ways to go.</p><p>你可以将这张表格解读为人类顺从的方式没有它们应有的效力，或者你可以把它解读为学者们认为在实验室里最容易做的事情的选择效应。前者是一个很大的论断，我需要更多的证据才能相信。后者对任何人来说都不是什么新闻。合成候选药物分子的速度很慢。免疫疗法的生产既慢又难。基因疗法还有很长的路要走。</p><p> Altogether it seems clear that our therapeutic armamentarium is lacking, whether in potency or ease of use.</p><p>总而言之，似乎很明显，我们的医疗设备无论是在效力上还是在易用性上都是缺乏的。</p><p>  Bringing a medical treatment to market is extremely slow and expensive.It  takes around a decade and $1 billion.A big reason for this is the  20% success rate for non-cancer drugs once they enter clinical trials, not to mention the definitely-less-than-100% success rate for making it to clinical trials in the first place.</p><p>将一种治疗药物推向市场是非常缓慢和昂贵的，大约需要10年和10亿美元，其中一个很大的原因是非癌症药物一旦进入临床试验就有20%的成功率，更不用说一开始进入临床试验的成功率肯定不到100%。</p><p> Here’s a figure from  this paper breaking down the costs, timelines, and success rates in a traditional target-based drug discovery campaign.</p><p>这是这篇论文中的一个数字，分析了传统的靶向药物发现活动的成本、时间表和成功率。</p><p>  Paraphrased caption from the paper:Numbers are in millions of USD and based on data from Eli Lilly and Company.p(TS) is the probability of successful transition from one stage to the next.WIP is work in process, the number of candidate drugs being worked on.Lighter-shaded boxes show calculated values based on assumed inputs.Costs do not include investments for exploratory discovery research, post-launch expenses like marketing, or non-R&amp;D overheads like non-scientist salaries.</p><p>论文说明：数字以百万美元为单位，基于礼来公司的数据。p(TS)是从一个阶段成功过渡到下一个阶段的概率。WIP是在制品，即正在研究的候选药物的数量。浅阴影框显示基于假设投入的计算值。成本不包括探索性发现研究的投资、上市后的费用(如市场营销)或非研发管理费用(如非科学家的工资)。</p><p> Worth noting in the figure is that most of the cost is in the clinical trials (the blue parts), and that the step with the lowest success rate is Phase 2 clinical trials (the first time the therapy’s efficacy is tested in humans, usually).</p><p>图中值得注意的是，大部分费用都在临床试验中(蓝色部分)，成功率最低的步骤是第二阶段临床试验(通常是第一次在人体上测试该疗法的疗效)。</p><p> What does this mean for longevity?Barring an adventure in regulatory arbitrage or  medical tourism, any longevity treatments will have to get through this process before they can get to you or me.  3So it may well be that the best way to pursue longevity is to improve the drug development process, depending on how tractable and neglected various improvements are.</p><p>这对长寿意味着什么？除非尝试监管套利或医疗旅游，否则任何长寿疗法都必须通过这个过程，才能达到你或我的效果。3因此，追求长寿的最好方式很可能是改进药物开发过程，这取决于各种改进有多容易处理和被忽视。</p><p> Diagnosing the problems in the drug development process is a lot like studying aging: everything you look at is broken, but we have no idea about the root causes or where best to intervene.</p><p>诊断药物开发过程中的问题很像研究衰老：你看到的一切都是坏的，但我们不知道根本原因或最好的干预方式。</p><p>  Animal models for disease are  fraught with  difficulty.Those for aging are  particularly  challenging.How challenging?So challenging that the longest-lived strain of mouse known to biology  used to be used as a model for  rapid aging, because the mice were being handled wrong and dying young.</p><p>疾病的动物模型充满了困难。那些关于衰老的动物模型尤其具有挑战性。挑战有多大？挑战如此之大，以至于生物学上已知的最长寿的小鼠品系曾被用作快速衰老的模型，因为小鼠被错误地处理，而且死得很早。</p><p> A big change in lab operations over the last two decades has been the “virtualization” of biotech, which is a fancy word for outsourcing.Work once done in-house, like synthesizing molecules or running toxicity assays, is now often done by Contract Research Organizations (CROs).Outsourcing carries all the advantages in biotech that it does in other domains: increased specialization, lower prices, etc.But outsourcing is inefficient at best, and usually involves many headaches.It’s still a lot easier to do drug development when everyone’s in the same building, or so says every ex-pharma scientist I’ve asked about it.This is not the case in other industries.</p><p>过去20年来，实验室运作的一个巨大变化是生物技术的“虚拟化”，这是外包的一个花哨的词。曾经在内部完成的工作，如合成分子或进行毒性测试，现在通常由合同研究机构(CRO)完成。外包具有生物技术在其他领域的所有优势：专业化程度提高，价格更低，等等。但外包充其量也是效率低下的，而且通常涉及很多棘手的问题。当所有人都在同一栋楼里时，药物开发仍然容易得多。我问过的每一位前制药科学家都是这么说的，但在其他行业情况并非如此。</p><p> Solutions to these problems could come in the form of automation —  Emerald Cloud Lab and  Transcriptic are two companies working on that — or better outsourcing offerings. One thing the field probably is good on is electronic lab notebooks; thanks though.</p><p>这些问题的解决方案可以以自动化的形式出现-Emerald Cloud Lab和Transcriptic是致力于此的两家公司-或者更好的外包服务。这个领域有一件事可能很不错，那就是电子实验室笔记本；不过，还是要谢谢你。</p><p>  Longevity research, and medicine in general, is bad at integrating its knowledge and learning from failures.Between 25% and 50% of clinical trial results  remain unpublished even several years after completion.This isn’t surprising: why publish your clinical data when there’s zero gain to you and even a slim chance you can repurpose the asset in the future?But this means a potential downside of moving longevity efforts from research to commercial therapeutic development is that the field will learn less overall.</p><p>长寿研究和整个医学在整合知识和从失败中吸取教训方面做得不好。即使在完成几年后，25%到50%的临床试验结果仍然没有发表。这并不令人惊讶：当你没有任何收获，甚至未来改变资产用途的机会微乎其微的时候，为什么还要公布你的临床数据呢？但这意味着将长寿努力从研究转移到商业治疗开发的潜在不利之处是，该领域整体上学到的东西会更少。</p><p> A related problem is that because liquidity events can happen far before convincing clinical data, biotechs are incentivized to push their risky studies until as late as possible (ideally after the employees get their money) and to gussy them up to look better than they really are.A fail-fast-and-publish-honestly mentality would of course be better for longevity overall.</p><p>一个相关的问题是，因为流动性事件可能会在令人信服的临床数据之前很久发生，生物技术公司会受到激励，把他们的高风险研究推迟到尽可能晚的时候(理想情况下是在员工拿到钱之后)，并美化它们，让它们看起来比实际情况更好。一种快速失败、诚实发表的心态当然会对整体寿命更有利。</p><p> Then again, it’s not like academic research is  necessarily better.Medical research results in general are  apparently  unreproducible up to 50% of the time.Plus private biotech can sometimes afford to do things that academia can’t.</p><p>话又说回来，并不是说学术研究就一定更好。医学研究结果通常在50%的情况下显然是不可复制的。另外，私营生物技术有时可以做学术界做不到的事情。</p><p>  Before it can conquer death, a longevity treatment will have to conquer the U.S. FDA’s clinical trial process.The FDA doesn’t consider aging to be a medical indication (a.k.a. a valid reason for treatment).This means longevity companies have to choose an existing age-related indication (e.g. Alzheimer’s) to demonstrate efficacy of their treatment on.How to do this well is a key consideration for any longevity biotech.</p><p>在战胜死亡之前，长寿疗法必须先征服美国FDA的临床试验过程，FDA并不认为衰老是一种医学适应症(又名。这意味着长寿公司必须选择现有的与年龄相关的适应症(例如阿尔茨海默氏症)来证明他们的治疗效果。如何做好这一点是任何长寿生物技术的关键考虑因素。</p><p> More optimistically, regulatory changes like  dual-track clinical trials or  eliminating phase 3 trials altogether might entail a massive acceleration in longevity therapeutic development.Outsourcing or decentralizing clinical trials is also an exciting option. Science 37 is one company working on this.</p><p>更为乐观的是，监管改革，如双轨临床试验或完全取消3期试验，可能会导致长寿治疗开发的大幅加速。外包或分散临床试验也是一个令人兴奋的选择。科学37是一家致力于此的公司。</p><p>  The high costs and failure rates of drug development make it a tough space for entrepreneurial disruption.(The first chapters  here are illustrative.)</p><p>药物开发的高成本和失败率使它成为创业破坏的艰难空间。(这里的第一章是说明性的。)。</p><p> This is partly because high risk makes behavior change hard.There’s natural resistance to changing any part of the playbook.As one medicinal chemist put it to me “if you make a service 2x better, nobody cares.If you make it 10x better, or tell them to try a new approach, they won’t believe you. 4x or 5x better with their existing process is optimal.”Not exactly culture of disruptive innovation.Genetic sequencing has managed to jump this gap; I’d like to better understand what degree of price decrease and reliability was required for that.</p><p>这在一定程度上是因为高风险使行为改变变得困难。改变剧本的任何部分都有天然的抵抗力。正如一位药物化学家对我说的那样，“如果你把一项服务提高两倍，没有人会在意。如果你把它提高10倍，或者告诉他们尝试一种新的方法，他们就不会相信你。”用他们现有的工艺提高4倍或5倍是最好的。“不完全是颠覆性创新的文化。遗传测序已经设法跨越了这一差距；我想更好地了解这需要多大程度的价格下降和可靠性。</p><p> It’s also because the payoffs in biotech take so long to arrive, way after all the research is done.This means platforms and services for drug development aren’t bought and sold by biotechs as much as bartered for with equity in whatever future drugs they hopefully produce.This in turn makes it more complicated and expensive to start companies offering platforms and services to biotechs compared to other industries.</p><p>这也是因为生物技术的回报需要很长时间才能到来，在所有研究完成之后。这意味着药物开发的平台和服务不是生物技术公司用股权交换的，而是他们希望生产的未来药物的股权。这反过来又使得与其他行业相比，开始为生物技术公司提供平台和服务的公司更加复杂和昂贵。</p><p> As if all the above wasn’t good enough, the time and cost required to make a drug are increasing over time, despite lots of technological advancement.There’s even a cute name for it:  Eroom’s law.Nobody knows why it’s happening, but if the causes of Eroom’s law are exogenous, we should advance more longevity therapeutics sooner while it’s relatively cheap.</p><p>似乎以上所有这些还不够好，尽管技术有了很大进步，但制造一种药物所需的时间和成本都在随着时间的推移而增加。它甚至有一个可爱的名字：eRoom定律。没有人知道为什么会发生这种情况，但如果Eroom定律的原因是外生的，我们应该在相对便宜的时候尽早推出更多的长寿疗法。</p><p> So, which has more marginal benefit, improving the drug discovery system or going after longevity with the existing system?Obviously I have no idea, but the point is that it’s  not obviously the latter.We should also appreciate how many important problems there are to be solved outside the lab and with non-biology skills.</p><p>那么，改进药物发现系统和用现有系统追求长寿，哪个更有边际效益呢？显然我不知道，但问题是不明显是后者，我们也应该认识到有多少重要的问题需要在实验室之外用非生物技能来解决。</p><p>   The pursuit of longevity doesn’t happen in a vacuum.A full answer to “should we pursue human longevity” needs to take all externalities into account.</p><p>追求长寿不是在真空中发生的，“我们是否应该追求人类长寿”的完整答案需要考虑到所有的外在因素。</p><p> A big externality is the aspirational value of longevity as a brand/meme for biotech in general.Some might argue that society is already working on longevity with every new medicine it develops.If we keep curing things that kill us, eventually we stop dying, right?Who needs the new branding?Well, a lot of longevity investment is not coming from traditional biotech/pharma investors, but from Silicon Valley.That may be attributable to the aspiration value.And even if the aspirational call of longevity does nothing more than encourage talented people to work on biotech, that may be well worth it.</p><p>一个很大的外部性是长寿作为生物技术的一个品牌/模因的期望价值。有些人可能会说，社会已经在用它开发的每一种新药来研究长寿。如果我们继续治愈那些杀死我们的东西，最终我们就不会死亡，对吗？谁需要新的品牌呢？嗯，很多长寿投资不是来自传统的生物技术/制药投资者，而是来自硅谷。这可能要归因于期望价值。即使渴望长寿的呼唤只会鼓励有才华的人从事生物技术工作，那可能也是非常值得的。</p><p> Another possibility is that the promise of death-postponement could spur funding increases or regulatory reforms for drug discovery.This is presumably the thinking behind efforts like  Rejuvenate,  Celevity, and  GenFlow to achieve longevity in charismatic species like household pets.If everyone’s dogs were suddenly living to age 30, people would hopefully start getting jealous.</p><p>另一种可能性是，延缓死亡的承诺可能会刺激药物发现的资金增加或监管改革。这大概就是像Rerenate、Clevity和GenFlow这样的努力背后的想法，这些努力旨在实现像家养宠物这样具有魅力的物种的长寿。如果每个人的狗都突然活到30岁，人们可能会开始嫉妒。</p><p> On the other hand, if a field over-promises and under-delivers it can go through a winter.This wasn’t great for the field of  AI, and it would be nice if longevity can avoid this.There’s also brand risk.Gene therapy was delayed a lot by the  death of a teenager in 1999.If longevity therapies develop brand recognition — I’m looking at you,  senolytics — and there’s a major adverse incident, it would have been better to keep a low profile.</p><p>另一方面，如果一个领域承诺过多而没有兑现，它可以度过一个冬天。这对人工智能领域来说不是什么好事，如果长寿可以避免这一点就好了。还有品牌风险。1999年一名青少年的死亡导致基因治疗被推迟了很长时间。如果长寿疗法能提高品牌认知度-我在看着你，感光者-而且有重大的不良事件，最好保持低调。</p><p> Then again, the same fears of death that make longevity prone to pseudoscience might act as a countervailing force to a winter. People don’t really care about AI research. They do care about staying alive.</p><p>话又说回来，同样的对死亡的恐惧使长寿倾向于伪科学，可能会起到抵消冬天的作用。人们并不真正关心人工智能研究。他们确实在乎活下去。</p><p>   Why do we care about longevity? Because death is bad.  4 There are four problems with it:</p><p>我们为什么要关心长寿呢？因为死亡是件坏事。4它有四个问题：</p><p>  But longevity isn’t the only solution to these problems. And these problems aren’t the only causes of suffering in the world that we might care about. This means we have two opportunity cost calculations to make.</p><p>但长寿并不是解决这些问题的唯一办法。这些问题并不是我们可能关心的世界上造成痛苦的唯一原因。这意味着我们要进行两个机会成本计算。</p><p>  Humanity has made a massive dent in problems 1 and 2 with analgesics.Analgesics get short shrift in the history of technology, but they’re one of the largest victories ever won against death, not to mention childbirth.They also have lots of room for improvement, though that improvement may be hard to attain if the history of analgesic development is  any  indication.Then again it’s hard to imagine it being any harder than longevity therapeutic development.</p><p>人类用镇痛剂在问题1和问题2上取得了巨大的进步。镇痛剂在技术历史上受到冷落，但它们是有史以来战胜死亡的最大胜利之一，更不用说分娩了。它们还有很大的改进空间，尽管如果止痛剂的发展历史有任何指示的话，这种改进可能很难实现。再一次，很难想象它会比长寿治疗开发更难。</p><p> Physical pain is hardly the only kind of suffering implicated in problems 1 and 2, of course.Aging and death, and witnessing them, entail  significant existential suffering and anguish.(Citation probably unnecessary for that fact.)If the psychonauts are to be believed, we may be close to treatments for those, too: clinical results so far are  promising.But it’s hard to imagine psychedelics making us fully disinterested in death.Doing so would likely require significant changes in analgesia, mood-altering drugs, and cultural attitudes toward medication and death.</p><p>当然，在问题1和问题2中，身体痛苦并不是唯一的一种痛苦。衰老和死亡，以及亲眼目睹它们，都会带来巨大的生存痛苦和痛苦。(因为这一事实，引用可能没有必要。)如果心理学家是可信的，我们也可能接近治疗这些痛苦的方法：到目前为止，临床结果是有希望的。但很难想象迷幻药让我们对死亡完全不感兴趣。要做到这一点，很可能需要在止痛、改变情绪的药物以及对药物和死亡的文化态度方面做出重大改变。</p><p> Some readers may feel that pain- or mood-manipulation are inauthentic ways to defy death.I’d gently remind such readers that we’re comparing these strategies against  making humans immortal, so you may want to check your naturalistic fallacy at the door.</p><p>一些读者可能会觉得控制痛苦或情绪是不真实的反抗死亡的方式，我会温和地提醒这样的读者，我们是在比较这些策略和让人类长生不老，所以你可能想在门口检查一下你的自然主义谬论。</p><p> Problems 3 and 4 run up against hairy philosophical issue</p><p>问题3和4遇到了毛骨悚然的哲学问题。</p><p>......</p><p>.</p></div><div id="story_share_this"><div class="sharethis-inline-share-buttons"></div></div><div class="text-break sotry_link page_narrow"><a target="_blank" href="https://milan.cvitkovic.net/writing/longevity/">https://milan.cvitkovic.net/writing/longevity/</a></div><div class="story_tags page_narrow"><button type="button" class="btn btn-light my_tag"><a href="/tag/追求/">#追求</a></button><button type="button" class="btn btn-light my_tag"><a href="/tag/human/">#human</a></button><button type="button" class="btn btn-light my_tag"><a href="/tag/长寿/">#长寿</a></button></div></div><div class="my_movie_list_item shadow p-3 mb-5 bg-white rounded"><button type="button" class="btn btn-link my_tag"><a href="/tag/web2.0/">#web2.0</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/google/">#google</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/设计/">#设计</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/游戏/">#游戏</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/创意/">#创意</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/apple/">#apple</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/苹果/">#苹果</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/摄影/">#摄影</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/软件/">#软件</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/美国/">#美国</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/iphone/">#iphone</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/图片/">#图片</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/手机/">#手机</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/视频/">#视频</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/广告/">#广告</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/免费/">#免费</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/谷歌/">#谷歌</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/网站/">#网站</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/windows/">#windows</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/微软/">#微软</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/下载/">#下载</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/firefox/">#firefox</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/音乐/">#音乐</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/linux/">#linux</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/blog/">#blog</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/博客/">#博客</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/程序/">#程序</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/艺术/">#艺术</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/web/">#web</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/wordpress/">#wordpress</a></button></div></div></div><div id="my_footer"><div class=""><a href="/tags/">tags</a> <a href="/users/">users</a></div>&copy; 2020 diglog.com </div></div></body></html>